Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Intangibles (2016 - 2025)

Vanda Pharmaceuticals' Intangibles history spans 16 years, with the latest figure at $117.1 million for Q4 2025.

  • For Q4 2025, Intangibles changed N/A year-over-year to $117.1 million; the TTM value through Dec 2025 reached $117.1 million, changed N/A, while the annual FY2025 figure was $117.1 million, N/A changed from the prior year.
  • Intangibles for Q4 2025 was $117.1 million at Vanda Pharmaceuticals, up from $115.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $121.4 million in Q4 2023 and bottomed at $17.8 million in Q2 2023.
  • The 5-year median for Intangibles is $20.3 million (2021), against an average of $56.3 million.
  • The largest YoY upside for Intangibles was 553.75% in 2023 against a maximum downside of 7.84% in 2023.
  • A 5-year view of Intangibles shows it stood at $20.1 million in 2021, then decreased by 7.55% to $18.6 million in 2022, then skyrocketed by 553.75% to $121.4 million in 2023, then fell by 4.55% to $115.8 million in 2024, then grew by 1.07% to $117.1 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Intangibles are $117.1 million (Q4 2025), $115.8 million (Q3 2024), and $121.4 million (Q4 2023).